NorthWest Biotherapeutics Inc (NWBO)

[Lykiri]

Thank you pgsd! I can't find additional information from others like David Jenkinson who took pictures last year. (Linda Liau presentation SNO2018)
Two interesting tweets IMO: first the mOS for the placebo group in the Randomized, placebo controlled trial of +/- ABT414/“Depatux-M”
and second the side effects after immunotherapy and pseudoprogression.

Sean Sachdev, MD

RTOG 3508 results at #SNO2019:

Randomized, placebo controlled trial of +/- ABT414/“Depatux-M” to standard of care (Stupp RT/TMZ) for GBM.
Negative overall. Benefit of PFS in EGFRvIII pts but no OS benefit even in that subgroup.

RTOG 3508 results at #SNO2019:

👉Randomized, placebo controlled trial of +/- ABT414/“Depatux-M” to standard of care (Stupp RT/TMZ) for GBM.

Negative overall. Benefit of PFS in EGFRvIII pts but no OS benefit even in that subgroup. #btsm pic.twitter.com/DVZNRNMqig

— Sean Sachdev, MD (@SeanSachdevMD) November 23, 2019

RTOG 3508 results at #SNO2019:

👉Randomized, placebo controlled trial of +/- ABT414/“Depatux-M” to standard of care (Stupp RT/TMZ) for GBM.

Negative overall. Benefit of PFS in EGFRvIII pts but no OS benefit even in that subgroup. #btsm pic.twitter.com/DVZNRNMqig

— Sean Sachdev, MD (@SeanSachdevMD) November 23, 2019

NIHBrainTumor

Our special volunteer Yamini Vyas discusses the association of common patient-reported #immunotherapy symptomatic side effects and pseudoprogression in patients with primary central nervous system tumors at #SNO2019. #BTSM Abstract: https://buff.ly/34lyVgw

Our special volunteer Yamini Vyas discusses the association of common patient-reported #immunotherapy symptomatic side effects and pseudoprogression in patients with primary central nervous system tumors at #SNO2019. #BTSM Abstract: https://t.co/oi51PSblRs pic.twitter.com/G7aoRk3woP

— NCI Neuro-Oncology Branch (@NIHBrainTumor) November 23, 2019

HOUT-04. ASSOCIATION OF COMMON PATIENT-REPORTED IMMUNOTHERAPY SYMPTOMATIC SIDE EFFECTS AND PSEUDOPROGRESSION IN PATIENTS WITH PRIMARY CENTRAL NERVOUS SYSTEM (CNS) TUMORS
Published: November 11, 2019


https://academic.oup.com/neuro-oncology/article-abstract/21/Supplement_6/vi112/5619717?redirectedFrom=fulltext

CONCLUSIONS

In contrast to the common pseudoprogression after chemoradiation, treatment-specific symptoms were worse with ICI-related pseudoprogression by MRI where an immunologic reaction was the likely cause of the imaging worsening. These results suggest that commonly used symptom and functional assessments to distinguish true progression from pseudoprogression may not be helpful with immunotherapy. Additional studies including those with pathologic confirmation of progression or pseudoprogression combined with outcomes measures are needed to develop more accurate determinations of disease status.